Business
Vasomune Therapeutics Inc., and AnGes Inc., Expand the Scope of the Co-Development Agreement to Target Additional Indications
TORONTO, November 25, 2025--Vasomune Therapeutics and AnGes Commit to Development of Additional Indications for Pegevongitide (AV-001).
About this update from Anges. Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":400,"url":"https://media.zenfs.com/en/business-wire.com/e49588d3b1cbb6f6f268d27228ff10f6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dBTI7g0dVX.ePCwC5DjhLQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTcwNTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/e49588d3b1cbb6f6f268d27228ff10f6","width":400,"height":400}},"lazy":false},{"type":"text","content":"TORONTO, November 25, 2025--(BUSINESS WIRE)--Vasomune Therapeutics Inc., and AnGes Inc., are pleased to announce that they have entered into an agreement to expand the research indications for the Tie2 receptor agonist Pegevongitide (AV-001) currently under joint development.","length":276,"tagName":"p"},{"type":"text","content":"To date, Vasomune and AnGes have been conducting clinical trials of Pegevongitide (AV-001), targeting Acute Respiratory Distress Syndrome arising from viral and bacterial pneumonia. Based on the mechanism and preclinical activity of Pegevongitide (AV-001), which stabilizes blood vessels and suppresses vascular leakage and inflammation, Vasomune and AnGes have assessed its potential applicability to other conditions, including cognitive impairment associated with hemodialysis. As a result, they have agreed to significantly expand the scope of their co-development efforts.","length":577,"tagName":"p"},{"type":"text","content":"This expanded agreement provides Vasomune with increased financial support and the ability to pursue more development opportunities to mitigate pathological vascular leakage.","length":174,"tagName":"p"},{"type":"text","content":"About Vasomune Therapeutics, Inc.","length":33,"tagName":"p"},{"type":"text","content":"Vasomune Therapeutics, Inc. is a private clinical-stage biopharmaceutical company developing the next generation of medicines to boost the body’s ability to defend against vascular leak. Founded in 2014, Vasomune has focused on vascular normalization strategies, and has progressed the lead candidate Pegevongitide (AV-001) from bench to bedside. Vascular dysfunction and vascular leak are associated with the pathology of several disease states, including bacterial and viral pneumonia and acute respiratory distress syndrome, sepsis, hemorrhagic shock, acute kidney injury, strok...